Evidence map›Paper›PMID 38645548›Full record

ArticleRadiology case reports2024

Interstitial lung disease with prolonged fever that occurred during long-term administration of olaparib in a 74-year-old ovarian cancer patient: Radiological features and considerations for preventing delayed diagnosis.

Yoshinobu Saito, Rei Yamaguchi, Takahiro Suzuki, Junpei Sato, Nobuhiko Nishijima, Sho Saito, Junichi Aoyama, Namiko Taniuchi, Masahiro Seike, Noriyuki Katsumata

Open access · goldAbstract readCase Reports
In one paragraph

Article in Radiology case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Yoshinobu SaitoDepartment of Pulmonary Medicine, Nippon Medical School Musashikosugi Hospital, Kanagawa, Japan.
Rei YamaguchiDepartment of Pulmonary Medicine, Nippon Medical School Musashikosugi Hospital, Kanagawa, Japan.
Takahiro SuzukiDepartment of Pulmonary Medicine, Nippon Medical School Musashikosugi Hospital, Kanagawa, Japan.
Junpei SatoDepartment of Pulmonary Medicine, Nippon Medical School Musashikosugi Hospital, Kanagawa, Japan.
Nobuhiko NishijimaDepartment of Pulmonary Medicine, Nippon Medical School Musashikosugi Hospital, Kanagawa, Japan.
Sho SaitoDepartment of Pulmonary Medicine, Nippon Medical School Musashikosugi Hospital, Kanagawa, Japan.
Junichi AoyamaDepartment of Pulmonary Medicine, Nippon Medical School Musashikosugi Hospital, Kanagawa, Japan.
Namiko TaniuchiDepartment of Pulmonary Medicine, Nippon Medical School Musashikosugi Hospital, Kanagawa, Japan.
Masahiro SeikeDepartment of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.
Noriyuki KatsumataDepartment of Medical Oncology, Nippon Medical School Musashikosugi Hospital, Kanagawa, Japan.
Nippon Medical School · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 74-year-old woman, who had been receiving olaparib for the treatment of ovarian cancer for more than a year, visited the emergency department complaining of a fever that had lasted for 1 month. She had been taking antipyretics and antibiotics for her fever, but without any effect. Although she had no symptoms other than fever, she had stopped taking olaparib for 1 week before her visit because she had developed anemia caused by myelosuppression from olaparib. After discontinuing olaparib, her maximum body temperature decreased. On admission, chest X-ray revealed no abnormalities, but chest CT showed diffuse ground-glass opacities. Chest CT taken 5 days later showed partial improvement; therefore, we diagnosed her with interstitial lung disease (ILD) associated with olaparib. After short-term steroid treatment, the ground-glass opacities disappeared, and the patient became afebrile. The CT scan taken for tumor evaluation 2 days before the onset of fever showed a few centrilobular nodular opacities and small patchy ground-glass opacities. These findings could indicate early lesions of ILD, but they seemed inconspicuous and nonspecific, and it might have been difficult to diagnose ILD then. To date, few cases of ILD associated with olaparib have been reported. However, based on previous reports, fever is often seen, and CT findings mainly comprise diffuse ground-glass opacities, and in some cases, centrilobular nodular shadows. Thus, in conjunction with the findings of the present case, these characteristics may be representative of olaparib-induced ILD.

Indexed as

Centrilobular noduleComputed tomographyFeverGround-glass opacityInterstitial lung diseaseOlaparib

Identifiers

PMID38645548
PMCPMC11026925
OpenAlexW4392612872

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.